GNLX GENELUX Corp
Pharmaceutical Preparations · Nasdaq · SEC CIK 1231457 · Fiscal year ends 12/31
Financial factors as of 2024-12-31 (2024Q4), TTM = sum of the last four quarters
Growth
TTM revenue YoY-95.3%
TTM net income YoY-5.6%
TTM EPS YoY18.1%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—
Margins
Gross margin—
Operating margin-396,200.0%
Net margin-373,362.5%
FCF margin-270,112.5%
EBITDA margin-393,262.5%
Returns
ROE-130.6%
ROA-95.4%
ROIC (approx.)-180.4%
Asset turnover0.00x
Leverage & solvency
Liabilities / assets24.3%
Debt / equity0.00x
Current ratio4.57x
Interest coverage—
Cash quality & payout
Operating cash flow / net income0.71x
Accruals ratio-27.6%
Payout ratio—
Capex / revenue4,762.5%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 |
|---|---|---|
| Income statement | ||
| Revenue | $8,000 | $8,000 |
| R&D expense | $19.85M | $19.00M |
| SG&A expense | $13.37M | $12.71M |
| Operating income | -$33.21M | -$31.70M |
| Net income | -$32.15M | -$29.87M |
| EBITDA | -$32.97M | -$31.46M |
| EPS (basic) | -0.86 | -0.95 |
| EPS (diluted) | -0.86 | -0.95 |
| Weighted avg. shares (diluted) | 37.18M | 31.45M |
| Balance sheet | ||
| Cash & equivalents | $5.33M | $8.56M |
| Short-term investments | — | $22.33M |
| Current assets | $15.13M | $31.55M |
| PP&E, net | $2.17M | $1.32M |
| Total assets | $19.03M | $34.72M |
| Current liabilities | $6.22M | $6.90M |
| Total liabilities | $7.48M | $8.44M |
| Shareholders' equity | $11.54M | $26.27M |
| Shares outstanding | 38.14M | 34.73M |
| Cash flow statement | ||
| Operating cash flow | -$25.27M | -$21.23M |
| Capital expenditure | $1.10M | $381,000 |
| Free cash flow | -$26.37M | -$21.61M |
| Investing cash flow | $12.14M | -$8.13M |
| Financing cash flow | $9.89M | $28.51M |
| Depreciation & amortization | $244,000 | $235,000 |
| Stock-based compensation | $5.87M | $5.74M |
Free plan shows the latest 2 periods; Pro shows all 4 🔒
· This company does not report gross profit in XBRL.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.